

ABSTRACT

A method of chemopreventing cancer by administering chemopreventive compositions of matter in an effective amount of at least one composition from a specific group of alpha-pyrone detailed in this invention formulated into a physiologically acceptable carrier medium.

REFEEENCES

Baum S.S., Hill R., Rommelspacher. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. *Prog Neuropsychopharmacol Biol Psychiatry* 1998;22(7):1105-20.

Jamieson D.D., Duffield P.H. The antinociceptive actions of kava components in mice. *Clin Exp Pharmacol Physiol* 1990;17(7):495-507.

Kretzschmar R., Meyer H.J. Comparative studies on the anticonvulsant activity of the pyrone compounds of *Piper methysticum* Forst. *Arch Int Pharmacodyn* 1969;177:261-267.

Norton SA, Ruze P. Kava dermatopathy. J Am Acad Dermatol 1994 Jul;31(1):89-97

Seitz U., Schule A., Gleitz J. [3H]-monoamine uptake inhibition properties of kavapyrones. *Planta Med* 1997;63:548-549.

Steiner GG. The correlation between cancer incidence and kava consumption. Haw Med J 2000;59(11):420-2

US5585386: Alpha-pyrone compositions for inducing/stimulating hair growth and/or retarding hair loss

US5981496: Alpha-pyrone compositions for treating alpha-pyrone responsive states

Voltz H.P., Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders in a randomized placebo-controlled 25-week outpatient trial. *Pharmacopsychiatry* 1997;30:1-5.

Warnecke G. Psychosomatic dysfunction in the female climacteric. Clinical effectiveness and tolerance of Kava Extract WS 1490. *Fortschr Med* 1991;109(4):119-22.